BioCentury
ARTICLE | Company News

CTTQ's tyrosine kinase inhibitor gets Chinese approval for NSCLC

May 11, 2018 9:18 PM UTC

The State Drug Administration (formerly CFDA) approved Focus V anlotinib from Chia Tai Tianqing Pharmaceutical Group Co. Ltd. (Nanjing, China) to treat advanced non-small cell lung cancer.

CTTQ has Chinese rights to anlotinib from Advenchen Laboratories LLC (Moorpark, Calif.), which developed the multi-target receptor tyrosine kinase inhibitor and retains rights elsewhere...